Standard Operating Procedure for Regulatory Sign-Off of Promotional and Non-Promotional Product Information
| Department | Regulatory Affairs |
| SOP No. | RA/2026/752 |
| Supersedes | NA |
| Page No. | 1 of X |
| Issue Date | 15/04/2026 |
| Effective Date | 15/04/2026 |
| Review Date | 15/04/2028 |
Purpose
This Standard Operating Procedure (SOP) defines the process for obtaining regulatory sign-off of all promotional and non-promotional product information to ensure compliance with applicable laws, regulations, and internal quality standards. The purpose is to maintain control over the content and accuracy of product information prior to release, thereby supporting risk mitigation, consistent messaging, and regulatory compliance within the pharmaceutical environment.
Scope
This SOP applies to all promotional and non-promotional product information materials including but not limited to brochures, leaflets, labeling, advertisements, digital media content, and product inserts within the Regulatory Affairs department. It covers materials intended for any dosage form, therapeutic area, and sales territory and involves all associated departments engaged in creation, review, and approval of such information. This SOP excludes internal communications and scientific publications not used for promotional or regulatory submission purposes.
Responsibilities
- Regulatory Affairs Team: Preparation and coordination of regulatory sign-off request.
- Quality Assurance: Review and verification of compliance with regulatory and quality standards.
- Medical Affairs: Scientific and clinical accuracy review where applicable.
- Marketing Department: Initial content preparation and alignment with promotional strategy.
- Legal Department: Review for legal compliance and claims substantiation.
- Approval Authority: Final sign-off ensuring all compliance points are fulfilled.
- Documentation Control: Maintenance and archival of all records related to sign-off.
Accountability
The Head of Regulatory Affairs is accountable for the implementation, compliance, periodic review, escalation of issues, and ensuring the effectiveness of this SOP. This role oversees training, timely sign-off processes, and manages corrective actions related to deviations from this procedure.
Procedure
This procedure outlines the detailed steps to be followed to achieve compliant regulatory sign-off of promotional and non-promotional product information.
1. Preparation and Prerequisites: All promotional and non-promotional materials must be complete and prepared as per the marketing brief and internal content guidelines. Preliminary reviews within the marketing and medical affairs teams shall be conducted prior to regulatory submission.
2. Submission for Regulatory Review: Regulatory Affairs will receive finalized draft documents and submit them to Quality Assurance, Medical Affairs, and Legal teams for review. The submission must include a completed regulatory sign-off request form and relevant background documents such as clinical data summaries, approved product labels, and therapeutic claims substantiation.
3. Review and Safety Checks: Each reviewing department will perform a thorough evaluation for accuracy, compliance with applicable regulatory guidelines (e.g., FDA, EMA), adherence to internal quality standards, and verification of claims and references. Any deficiencies or discrepancies shall be documented and communicated back to the originator for correction.
4. Revisions and Resubmission: If changes are required, the material originator revises the material accordingly. Regulatory Affairs coordinates the incorporation of revisions and resubmits the updated materials for final review.
5. Final Approval and Sign-Off: Upon satisfactory completion of reviews, the designated Approval Authority (e.g., Head of Regulatory Affairs or delegated senior personnel) will provide formal sign-off. The sign-off must be documented electronically or on authorized forms with date, signature, and comments if any.
6. Documentation and Record Retention: All documentation including original materials, review comments, sign-off forms, and related correspondence shall be archived as per the document control policy for a minimum retention period compliant with regulatory requirements.
7. Handling Deviations and Change Control: Any deviations from this SOP or late-stage changes to approved materials must be documented via the deviation and change control procedures respectively. Such cases require re-approval prior to use.
8. Training and Awareness: Relevant personnel shall receive training on this SOP to ensure understanding of roles, responsibilities, and compliance requirements.
Following these steps ensures that all promotional and non-promotional product information released is accurate, compliant, and aligned with regulatory expectations, thus reducing risk and enhancing corporate governance.
Abbreviations
- SOP – Standard Operating Procedure
- QA – Quality Assurance
- RA – Regulatory Affairs
- EMA – European Medicines Agency
- FDA – Food and Drug Administration
- GMP – Good Manufacturing Practice
- MA – Medical Affairs
Documents
Key documents supporting this SOP include:
- Regulatory Sign-Off Request Form (Annexure-1)
- Review and Approval Checklist for Product Information (Annexure-2)
- Deviation and Change Control Log (Annexure-3)
References
- FDA Guidance for Industry on Advertising and Promotion
- EMA Guideline on the Quality of Advertising and Promotion
- ICH Q7 Good Manufacturing Practice Guide
- Corporate Quality Management System Documentation
- Internal Document Control and Compliance Policies
Version
1.0
Approval
| Prepared By | |
| Checked By | |
| Approved By |
Annexures
Annexure-1: Regulatory Sign-Off Request Form
Purpose: To formally request regulatory review and sign-off for promotional and non-promotional product information.
| Document Number | RA-SORF-2026-001 |
| Date of Request | 15/04/2026 |
| Product Name | Sample Product X |
| Dosage Form | Tablet |
| Material Type | Brochure – Promotional |
| Marketing Contact | Marketing Dept. |
| Regulatory Contact | Regulatory Affairs Dept. |
| Supporting Documentation Attached | Yes |
| Requester Signature | __________________ |
| Date | 15/04/2026 |
| Regulatory Reviewer Comments | __________________ |
| Regulatory Reviewer Signature | __________________ |
| Date | 16/04/2026 |
| Approval Authority Signature | __________________ |
| Date | 17/04/2026 |
Annexure-2: Review and Approval Checklist for Product Information
Purpose: To systematically verify accuracy, compliance, and completeness of promotional and non-promotional product information prior to sign-off.
| Checklist Item | Checked (Yes/No) | Comments |
|---|---|---|
| Accuracy of Clinical Claims | Yes | Verified against approved label and clinical data. |
| Compliance with Regulatory Guidelines | Yes | Follows FDA and EMA advertising rules. |
| Consistency with Approved Labeling | Yes | Aligned with current product label. |
| Legal Review Completed | Yes | No issues identified. |
| Formatting and Branding Compliance | Yes | Matches corporate branding standards. |
| Final Approval Obtained | Yes | Signed by authorized personnel. |
Annexure-3: Deviation and Change Control Log
Purpose: To document and track deviations or changes from approved promotional and non-promotional product information documents and procedures.
| Deviation/Change ID | Date | Description | Status | Comments |
|---|---|---|---|---|
| DEV-2026-015 | 12/03/2026 | Late change in product claims during review | Closed | Reviewed and re-approved accordingly |
| CHG-2026-009 | 05/04/2026 | Correction in branding artwork | Closed | Change control implemented |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
| 15/04/2026 | 1.0 | Initial issue | New SOP creation |